Patients who are cN0 with HER2-positive or triple-negative breast cancer who receive full neoadjuvant chemotherapy may be ideal candidates for axillary surgery deescalation if they have a breast pathologic complete response (pCR), according to a new study. The findings were presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care (abstract 12).
Deescalation of axillary surgery demands careful patient selection. In the new study, researchers sought to